A new drug has received U.S. Food and Drug Administration (FDA) approval, in which the Barbara Ann Karmanos Cancer Institute played a crucial role. The oral targeted menin inhibitor ziftomenib (known by its brand name Komzifti™) received FDA approval on Nov. 13, 2025. Ziftomenib is a once-daily oral targeted therapy for adult patients with nucleophosimin 1 (NPM1)-mutated acute myeloid leukemia (AML). “AML is an aggressive blood and bone marrow cancer, and mutations in the NPM1 gene are among the most co...